Medscape ALYATEC


A clinical study conducted by ALYATEC was featured on Medscape, a website focusing on medical news.

It highlights the results of a phase 2 study which aimed to assess the efficacy of low-dose interleukin-2 (IL-2) biotherapy on nasal symptoms in the event of allergic rhinitis to birch pollen. 24 patients were repeatedly exposed to birch allergens in ALYATEC environmental exposure chamber.

The results obtained are promising and constitute a potential lead for an anti-allergic immunotherapy according to Pr. Frédéric de Blay, principal investigator of the study, medical expert of ALYATEC and pneumo-allergologist at the Strasbourg University Hospital.

The full article can be read on Medscape’s website.